Search results
Results from the WOW.Com Content Network
SOUTH SAN FRANCISCO, Calif. and BERLIN, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Bayer today announced they have entered into a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive ...
Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto. "The funding that is ...
Under the terms of their license and collaboration agreement, Bayer is responsible for all the clinical development of BAY 1905254 and its future commercialization worldwide, if the therapy is approved. In September 2018, Bayer initiated patient dosing in a Phase 1 trial assessing the safety and tolerability of BAY 1905254.
"This partnership leverages Bayer's established European cardiovascular infrastructure and enables us, via substantial cost-savings, to focus our r BridgeBio Pharma, Bayer agree on licensing deal ...
Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies Compugen to hold 2 nd Quarter Conference Call August 7, 2013 TEL AVIV, Israel--(BUSINESS ...
By 2015, Recursion had closed its Series A round of funding and signed a research agreement with Sanofi Genzyme. [14] In 2020, the company received $50 million equity investment from Bayer during its Series D funding round. [15] [16] The company listed on the Nasdaq Stock Exchange on April 20, 2021 under the ticker symbol RXRX.
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) also sets out specific provisions that shall be followed if a compulsory license is issued, and the requirements of such licenses. The TRIPS compulsory licensing framework was originally enshrined in its entirety within Article 31.
Based on the agreement, the site would perform the final fill-finish of various biologics products produced by WuXi's API sites, and act as a backup for filling operations for Bayer's Kovaltry anti-hemophilic infusions which are primarily finished in another plant in Berkeley, California.